Search results

1 – 4 of 4
Per page
102050
Citations:
Loading...
Access Restricted. View access options
Book part
Publication date: 25 July 2008

Ravi Madhavan, Turanay Caner, John Prescott and Balaji Koka

In the network strategy view, relative competitive advantage stems not merely from opportunity structures embedded in networks but also from the distribution of ability and…

Abstract

In the network strategy view, relative competitive advantage stems not merely from opportunity structures embedded in networks but also from the distribution of ability and motivation among firms. Thus, there is a need to “bring the firm back in” to the network strategy narrative. We demonstrate that a mixed-methods design, blending large-sample data with micro-data on specific firms and their networks, can increase our understanding of the interplay of network structure and actor mechanisms, thus bridging the chasm between theory and practice in network strategy. We believe this is a critical step toward the “strategic design of networks.”

Details

Network Strategy
Type: Book
ISBN: 978-0-7623-1442-3

Access Restricted. View access options
Article
Publication date: 12 April 2013

Turanay Caner and Beverly B. Tyler

The purpose of this paper is to examine whether alliance portfolio R&D intensity contributes to biopharmaceutical firms' number of new product approvals and whether alliance…

733

Abstract

Purpose

The purpose of this paper is to examine whether alliance portfolio R&D intensity contributes to biopharmaceutical firms' number of new product approvals and whether alliance portfolio R&D intensity is more positively related to the number of new product approvals for pharmaceutical firms than for biotechnology firms.

Design/methodology/approach

The paper employs a random effects Poisson regression model using panel data of 821 firm year observations for 146 biopharmaceutical firms operating in the USA. The robustness of results is also checked with additional analysis, provided in an appendix.

Findings

The results of this study show that the R&D intensity of firms' alliance portfolios is positively related to their new product introductions. It is also found that alliance portfolio R&D intensity has a more positive impact on the pharmaceutical segment of the industry's new product introductions than those of the biotechnology segment.

Originality/value

The authors develop and test theory about how the combined effects of two dimensions of alliance portfolio configuration (size and relationship strength) positively impact new product development. The authors propose a two dimensional alliance portfolio configuration measure, alliance portfolio R&D intensity. They combine the number of R&D alliances relative to the total number of alliances in the portfolio with the differential strength of ties associated with resource commitments required to source information from upstream and downstream alliances.

Details

American Journal of Business, vol. 28 no. 1
Type: Research Article
ISSN: 1935-519X

Keywords

Available. Content available
Book part
Publication date: 25 July 2008

Abstract

Details

Network Strategy
Type: Book
ISBN: 978-0-7623-1442-3

Access Restricted. View access options
Book part
Publication date: 25 July 2008

Two core assumptions set network theory apart from other perspectives and direct research into specific strategic and organizational topics.

Abstract

Two core assumptions set network theory apart from other perspectives and direct research into specific strategic and organizational topics.

Details

Network Strategy
Type: Book
ISBN: 978-0-7623-1442-3

1 – 4 of 4
Per page
102050